NCT00824850View on ClinicalTrials.gov

Study Evaluating Prevnar Infant Long-term Immune Response Versus Prevnar Naive Cohort

PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
Pneumococcal Conjugate Vaccine
Interventions
BIOLOGICAL

13-valent Pneumococcal Conjugate Vaccine

single injection, single dose, single site, 0.5 mL per dose.

BIOLOGICAL

13-valent Pneumococcal Conjugate Vaccine

single injection, single dose, single site, 0.5 mL per dose.

Trial Locations (2)

94545

Pfizer Investigational Site, Hayward

95119

Pfizer Investigational Site, San Jose

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00824850 - Study Evaluating Prevnar Infant Long-term Immune Response Versus Prevnar Naive Cohort | Biotech Hunter | Biotech Hunter